Cargando…
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure after frontline immunochemotherapy
Patients with advanced‐stage follicular lymphoma (FL) who progress early after receiving first‐line therapy have poor overall survival (OS). Currently applied clinical prognostic models such as FL International Prognostic Index [FLIPI], FLIPI‐2 and PRIMA‐Prognostic Index [PRIMA‐PI] have suboptimal s...
Autores principales: | Mir, Farheen, Mattiello, Federico, Grigg, Andrew, Herold, Michael, Hiddemann, Wolfgang, Marcus, Robert, Seymour, John F., Bolen, Christopher R., Knapp, Andrea, Nielsen, Tina, Casulo, Carla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756469/ https://www.ncbi.nlm.nih.gov/pubmed/32815559 http://dx.doi.org/10.1002/ajh.25973 |
Ejemplares similares
-
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
por: Townsend, William, et al.
Publicado: (2023) -
Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
por: Herold, Michael, et al.
Publicado: (2022) -
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy
por: Jamois, Candice, et al.
Publicado: (2019) -
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression
por: Seymour, John F., et al.
Publicado: (2019) -
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022)